Home › Results from Mercks Phase 3 Study of Investigational Chronic Hepatitis C Therapy Elbasvir/Grazoprevir in Patients with Advanced Chronic Kidney Disease Published in The Lancet
 

Keywords :   


Results from Mercks Phase 3 Study of Investigational Chronic Hepatitis C Therapy Elbasvir/Grazoprevir in Patients with Advanced Chronic Kidney Disease Published in The Lancet

2015-10-06 01:01:00| Merck.com - Research & Development News

Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the publication of results from C-SURFER, the first Phase 31 clinical trial to investigate an all-oral, ribavirin-free chronic hepatitis C virus (HCV) treatment regimen in treatment-nave and treatment-experienced patients with advanced chronic kidney disease (CKD) stages 4 or 5 and chronic HCV genotype 1 (GT1) infection. Language: English Contact: MerckMedia Contacts:Doris Li, 908-246-5701Sarra Herzog, 201-669-6570orInvestor Contacts:Teri Loxam, 908-740-1986Justin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: in the results advanced

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
15.05Attitudes EWG Verified Skincare Line Oceanly Expands with SPF Offerings
15.05Sherwin-Williams Packaging Coatings Expands Non-BPA Coatings Production in Europe
15.05Voesh Unveils Body Refining Roller Crme Ahead of Summer 2024
15.05KANSAI HELIOS Completes Acquisition of WEILBURGER Coatings
15.05Portugal\'s Etifam adds Screen Truepress Label 350UV SAI-E
15.05Tom Hardy Is Jo Malone Londons New Ambassador for Cypress & Grapevine Cologne Intense
15.05Mooncat Introduces New Hue, Holds Bi-Annual Sale
15.05Eastern North Pacific Tropical Weather Outlook
More »